StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research report issued on Tuesday. The brokerage set a “sell” rating on the stock.

Oragenics Trading Up 18.9 %

Oragenics stock opened at $0.41 on Tuesday. The stock has a 50 day moving average of $0.34 and a 200-day moving average of $0.66. The stock has a market cap of $5.01 million, a P/E ratio of -0.06 and a beta of 0.40. Oragenics has a 52 week low of $0.25 and a 52 week high of $6.42.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.